Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clarinex-D 24-hour approved

This article was originally published in The Tan Sheet

Executive Summary

FDA clears the Rx desloratadine 5 mg/pseudoephedrine sulfate 240 mg combination "for relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis (outdoor allergies), including nasal congestion, in patients 12 years of age and older," Schering-Plough announces March 4. The agency approved the extension following review of two randomized, parallel group clinical trials evaluating 2,852 subjects ages 12 to 78 over two weeks; 708 participants received Clarinex-D. "In both trials, the antihistaminic efficacy of Clarinex-D 24-Hour, when examining symptoms of allergic rhinitis excluding nasal congestion, was significantly greater than pseudoephedrine or Claritin 5 mg alone," Schering says. Availability of the non-sedating antihistamine tablets will coincide with the spring allergy season...

Topics

UsernamePublicRestriction

Register

PS097922

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel